Bradley Foster & Sargent Inc. CT raised its stake in Johnson & Johnson (NYSE: JNJ – Get Rating) by 5.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 354,956 shares of the company stock after purchasing an additional 19,525 shares during the quarter. Johnson & Johnson accounts for about 1.3% of Bradley Foster & Sargent Inc. CT’s portfolio, making the stock its 19th biggest position. Bradley Foster & Sargent Inc. CT’s holdings in Johnson & Johnson were worth $ 60,722,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors also recently modified their holdings of JNJ. Schrum Private Wealth Management LLC purchased a new stake in shares of Johnson & Johnson during the fourth quarter valued at approximately $ 1,426,000. Kozak & Associates Inc. increased its position in shares of Johnson & Johnson by 1.7% during the fourth quarter. Kozak & Associates Inc. now owns 6,426 shares of the company stock valued at $ 1,090,000 after acquiring an additional 108 shares during the last quarter. Evergreen Capital Management LLC increased its position in shares of Johnson & Johnson by 2.6% during the fourth quarter. Evergreen Capital Management LLC now owns 122,092 shares of the company stock valued at $ 20,886,000 after acquiring an additional 3,046 shares during the last quarter. City State Bank purchased a new stake in shares of Johnson & Johnson during the fourth quarter valued at approximately $ 2,288,000. Finally, Gill Capital Partners LLC increased its position in shares of Johnson & Johnson by 16.9% during the fourth quarter. Gill Capital Partners LLC now owns 2,226 shares of the company stock valued at $ 381,000 after acquiring an additional 321 shares during the last quarter. 68.78% of the stock is owned by hedge funds and other institutional investors.
In related news, insider William Hait sold 29,699 shares of Johnson & Johnson stock in a transaction on Thursday, April 21st. The stock was sold at an average price of $ 183.58, for a total transaction of $ 5,452,142.42. Following the completion of the sale, the insider now owns 80,236 shares of the company stock, valued at $ 14,729,724.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Kathryn E. Wengel sold 40,000 shares of the firm’s stock in a transaction dated Friday, June 10th. The shares were sold at an average price of $ 173.00, for a total value of $ 6,920,000.00. Following the sale, the executive vice president now owns 71,311 shares in the company, valued at approximately $ 12,336,803. The disclosure for this sale can be found here. Insiders have sold 78,161 shares of company stock valued at $ 13,895,302 in the last three months. 0.35% of the stock is owned by corporate insiders.
Johnson & Johnson stock opened at $ 169.46 on Friday. Johnson & Johnson has a one year low of $ 155.72 and a one year high of $ 186.69. The business has a fifty day moving average price of $ 178.10 and a 200-day moving average price of $ 172.89. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.39 and a quick ratio of 1.14. The firm has a market capitalization of $ 445.92 billion, a P / E ratio of 22.84, a PEG ratio of 3.35 and a beta of 0.66.
Johnson & Johnson (NYSE: JNJ – Get Rating) last posted its quarterly earnings results on Tuesday, April 19th. The company reported $ 2.67 EPS for the quarter, topping analysts’ consensus estimates of $ 2.60 by $ 0.07. Johnson & Johnson had a return on equity of 36.59% and a net margin of 20.90%. The firm had revenue of $ 23.43 billion during the quarter, compared to analyst estimates of $ 23.62 billion. During the same period last year, the company earned $ 2.59 earnings per share. The business’s revenue for the quarter was up 5.0% on a year-over-year basis. Sell-side analysts expect that Johnson & Johnson will post 10.23 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 7th. Investors of record on Tuesday, May 24th were paid a dividend of $ 1.13 per share. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $ 1.06. The ex-dividend date was Monday, May 23rd. This represents a $ 4.52 annualized dividend and a yield of 2.67%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 60.92%.
A number of analysts recently commented on JNJ shares. Credit Suisse Group increased their price target on Johnson & Johnson from $ 200.00 to $ 205.00 and gave the company an “outperform” rating in a research report on Wednesday, April 20th. The Goldman Sachs Group raised their target price on Johnson & Johnson from $ 163.00 to $ 181.00 and gave the stock a “neutral” rating in a research report on Tuesday, April 12th. Morgan Stanley decreased their target price on Johnson & Johnson from $ 175.00 to $ 173.00 and set an “equal weight” rating for the company in a research report on Wednesday, April 6th. Bank of America began coverage on Johnson & Johnson in a research report on Wednesday, March 2nd. They issued a “neutral” rating for the company. Finally, Sanford C. Bernstein downgraded Johnson & Johnson from an “outperform” rating to a “market perform” rating and raised their target price for the stock from $ 180.00 to $ 183.00 in a research report on Wednesday, March 16th. Four research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Johnson & Johnson presently has a consensus rating of “Buy” and an average price target of $ 190.50.
Johnson & Johnson Company Profile: (Get Rating)
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health / beauty products under the AVEENO, CLEAN & CLEAR, DR.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE: JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily: – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.